

Radioisotope production for medicine

at **DONES**



UNIVERSIDAD
DE GRANADA

Javier Praena
Ignacio Porras
Fernando Arias de Saavedra
Andrés Roldán
Elena López Melero (PhD)



Investigación industrial en tecnologías y procesos
aplicados a IFMIF-DONES para poder evolucionar
en el programa de fusión

DONES-EVO

Ciemat


Centro de Investigaciones
Energéticas, Medioambientales
y Tecnológicas

Fernando Mota
Maribel Ortiz

- **Social justification.**
- **Economic justification.**
- **At DONES every step, from production to patient, is completely new: INNOVATION.**
- Several conventional and new radioisotopes are possible at DONES
- Conventional and new radiopharmaceuticals will be needed.
- Conventional radioisotope could need a new process to get the radiopharmaceutical.
- **This talk is focused on neutron and deuterons and:**
 - **$^{99}\text{Mo}/^{99\text{m}}\text{Tc}$.**
 - **80% of all diagnostic medical scans worldwide.**
 - **^{177}Lu .**
 - **Emergent theranostic (diagnosis and therapy) and in expansion.**

Social justification

- **Radioisotopes and radiopharmaceutical are key for:**
 - **Diagnosis of cardiovascular and cancer diseases.**
 - **Therapy in cancer.**
 - **PET technique Alzheimer.**



World Health Organization Health Topics Countries Newsroom Emergencies Data

GHO Home Indicators Countries Data API Map Gallery Publications Data

GHO Home Indicators Countries Data API Map Gallery Publications Data Search

Top 10 causes of death in United States of America for both sexes aged all ages (2019)

[Hide filters](#) | [Top-10 deaths](#) | [Top-10 DALYs](#) | [Underlying data](#) | [Download with OData API](#)


Filters

Country
United States of America

Year
2019


Sex
Both sexes

Age group
All ages



Death in Spain for both sexes aged all ages (2019)

10 DALYs | [Underlying data](#) | [Download with OData API](#)



Economic justification

ATTRACTIVE OPPORTUNITIES IN THE NUCLEAR MEDICINE MARKET

Market growth in the APAC can be attributed to the increasing research initiatives in Japan, rising installations of PET scanners in India and China, and initiatives by the Australian government



Growth in this market is mainly driven by the increasing incidence and prevalence of cancer and cardiovascular diseases and the need to reduce the demand and supply gap of Mo-99.




Emerging countries are expected to offer potential growth opportunities for market players during the forecast period.

NUCLEAR MEDICINE MARKET GLOBAL FORECAST TO 2028 (USD BN)



CAGR OF
11.3%

The global nuclear medicine market is expected to be worth USD 9.4 billion by 2028, growing at a CAGR of 11.3% during the forecast period.



The European nuclear medicine market is projected to reach USD 2.2 billion by 2028, growing at a CAGR of 11.3% during the forecast period



Hospital budget cuts and high equipment costs are expected to pose a challenge to the growth of this market.

The Mo/Tc is anticipated to account for a major share of the global market for radiopharmaceuticals by 2031

The pathway of radioisotopes: no time to lose

Production



Nuclear Reactors



Cyclotrons



Processing



Hospitals



Innovation at DONES:
Different nuclear reactions.
Nuclear reactors $(n,\gamma) \rightarrow$ DONES $(n,2n)$
Cyclotrons $(18p,x) \rightarrow$ DONES $(40d,x)$

Innovation at DONES:
Different processing for conventional radioisotope to radiopharmaceutical.
New radioisotope...

Innovation at DONES:
New radiopharmaceuticals and new radioisotopes.


Different contaminations, different experimental setups

$^{99}\text{Mo}/^{99\text{m}}\text{Tc}$: where is produced at present? Few nuclear reactors

From fission of Uranium (high production)

Or

Neutron capture: $^{98}\text{Mo}(n,\gamma)^{99}\text{Mo}$ (medium production)



The reactor must be designed in advance for producing ^{99}Mo

$^{99}\text{Mo}/^{99\text{m}}\text{Tc}$: Molybdenum world crisis 2009-2010

**Unexpected stops at the same period of few nuclear reactors.
Important delays in diagnosis (80% of total!!!).**



nature International weekly journal of science
nature news home | news archive | specials | opinion | features | news blog | natur

Published online 23 October 2008 | Nature | doi:10.1038/news.2008.1196

Europe's isotope shortage will continue into 2009

Hospitals forced to use substitute procedures for medical scans.

Paula Gould

A Europe-wide shortage of medical isotopes will continue for at least three months while a Dutch nuclear reactor is repaired. Governments and regulators are now bending their rules concerning the use and transport of radioactive materials so that patients can still undergo diagnostic tests during the supply crisis.


The High Flux Reactor in Petten, the Netherlands, is facing an extended shut-down.



NRG

This article elsewhere

- Links linking to this article
- Add to Digg
- Add to Facebook
- Add to Newsline
- Add to del.icio.us
- Add to Twitter



nature International weekly journal of science
Home | News & Comment | Research | Careers & Jobs | Current Issue | Archive | Audio & Video | For Authors

Active | Volume 504 | Issue 7478 | News Feature | Article

NATURE | NEWS FEATURE


Radioisotopes: The medical testing crisis

With a serious shortage of medical isotopes looming, innovative companies are exploring ways to make them without nuclear reactors.

Richard Van Noorden

11 December 2013

PDF | Rights & Permissions



Many diagnostic scans rely on radioactive technetium-99m.

In 2009, two nuclear research reactors shut down for repairs and maintenance. This was not surprising, given that both were around half a century old. But these reactors happened to produce most of the world's supply of the radioactive tracer technetium-99m, an isotope injected into patients in 70,000 diagnostic scans a day. Hospitals around the world went into a panic.

Last small crisis in Spain

ANNUAL REVIEWS

2020

Annual Review of Nuclear and Particle Science

The Shortage of Technetium-99m and Possible Solutions

Thomas J. Ruth

TRUTH, Vancouver, British Columbia V6T2A3, Canada; email: truth@truth.ca

There is a follow-up of the situation of the Mo/Tc by international agencies.

ANNUAL REVIEW CONNECT

www.annualreviews.org

- Download figures
- Request editorial changes
- Forward search
- Register related articles
- Show us email or social media

Ann. Rev. Nucl. Part. Sci. 2020. 70:77-94
First published as a Review in Advance on June 1, 2020

The Annual Review of Nuclear and Particle Science is online at annualreviews.org
<https://doi.org/10.1146/annurev-nucl-012020-010000>



Keywords

HEU, LEU, ^{99}Mo , $^{99\text{m}}\text{Tc}$, reactor, accelerator


Abstract

Following a major shortage of ^{99}Mo in the 2009-2010 period, concern grew that the aging reactor production facilities needed to be replaced.

$^{99}\text{Mo}/^{99\text{m}}\text{Tc}$: where at DONES? Test Cell



$^{99}\text{Mo}/^{99\text{m}}\text{Tc}$: at DONES different reaction with natural target



$^{99}\text{Mo}/^{99\text{m}}\text{Tc}$: production at DONES

Behind of HFTM	6 irradiation day (GBq/g of Mo)
Shutdown	~ 48,2
5 days decay	~10

Comparable with medium production at nuclear reactors.



$^{100}\text{MoO}_3$ enriched samples, the regional demand of Andalucía could be satisfied, most conservative.

Other radioisotopes could be produced simultaneously.

But in/out device from Test Cell modifies the production...

$^{99}\text{Mo}/^{99\text{m}}\text{Tc}$: in/out device modifies production

Inserción lateral






- ✓ Permite insertar muestras automáticamente con periodos programables de tiempo de irradiación
- ✓ Máximo aprovechamiento del área de mayor flujo neutrónico detrás del HFTM
- ✓ Posibilidad de irradiar grandes volúmenes: $\sim 100 \text{ cm}^3$.
- ✓ **Ejemplo:** 6 días de irradiación para ^{100}Mo (95%)
 - Producción estimada de $\sim 13 \text{ TBq}$ de $^{99}\text{Mo}/^{99\text{m}}\text{Tc}$.
 - Cubre las necesidades del **70% de la población de España**

Retos:

- ✓ Mantener la estanqueidad de la Test Cell
- ✓ Conservar los requisitos de blindaje radiológico de la TC
- ✓ Soportar las extremas condiciones de irradiación

$^{99}\text{Mo}/^{99\text{m}}\text{Tc}$: in/out device modifies production

Inserción Rabbit ~ STUMM



Sección horizontal


- ✓ No hay cambios de diseño del blindaje de la TC, porque utiliza los tubos que pasan por los PCP.
- ✓ **Ejemplo:** 6 días de irradiación para ^{100}Mo (95%):
 - Producción estimada de ~ 2 TBq de $^{99}\text{Mo}/^{99\text{m}}\text{Tc}$.
 - Cubre las necesidades del **100 % de Andalucía**.

Retos (los mismos):

- ✓ Soportar las extremas condiciones de irradiación
- ✓ Diseñar de los tubos del sistema Rabbit para evitar bloqueos.


^{177}Lu is the most emerging radioisotope

- Theragnostic = diagnosis and therapy.
- Versatile radioisotope and one the most important emergent radioisotopes.
- Currently, ^{177}Lu (6.7 d) is under study for several other tumours with good results.



Number of scientific publications vs time:

Therapeutic applications of ^{90}Y and ^{177}Lu




^{177}Lu : where at DONES?

Not using neutrons (low production at TC)

Using **deuterons** on natural $^{176}\text{Y}_2\text{O}_3$ target: **innovation.**



Two reactions produce Lutetium-177 with deuterons:



^{177}Lu : where at DONES?





Possible deuteron beam deflection to R026 at 40 MeV and 1.25 mA

- Simultaneous to the irradiation of the Li target



^{177}Lu : innovation in production setup

Deuteron beam



A realistic device is designed to sustain the power.

^{177}Lu : production at DONES


	Specific Activity (GBq/mg)	Days	Reaction
Nuclear Reactors	1,11	7	$^{176}\text{Yb}(n,\gamma)^{177}\text{Yb}\rightarrow^{177}\text{Lu}$
DONES	1,11	3	$^{176}\text{Yb}(d,p/n)^{177}\text{Yb}\rightarrow^{177}\text{Lu}$

Same production in half of the time!!!

More radioisotopes are under studied

	Vida	Reacción Convencional	Blanco	Reacción en DONES	Aplicación
^{11}C	20 min	$p + ^{14}\text{N}$	gas	$^{10}\text{B(d,n)}$ baja	Multitud de diagnósticos PET
^{13}N	10 min	$p + ^{13}\text{C}$	sólido	$^{12}\text{C(d,n)}$ baja E	Diagnósticos PET en cardiología
^{15}O	2 min	$p + ^{15}\text{N}$	gas	$^{14}\text{N(d,n)}$ baja E	Diagnósticos PET en cardiología
^{18}F	110 min	$p + ^{18}\text{O}$	líquido	$d + ^{20}\text{Ne} \rightarrow \alpha + ^{18}\text{F}$	Multitud de diagnósticos PET
$^{68}\text{Ge}/^{68}\text{Ga}$	270 d / 68 min			$^{69}\text{Ga(d,3n)}$ alta E	Diagnósticos PET del cáncer
^{64}Cu	762 min			$^{63}\text{Cu(d,p)}$ baja E	InmunoPET y terapia
^{89}Zr	78 h			$^{89}\text{Y(d,2n)}$ alta E	PET metabólico
^{44}Sc	4h/58h			$^{44}\text{Ca(d,2n)}$ alta E	Gamma-PET
$^{94\text{m}}\text{Tc}$	52 min			$^{92}\text{Mo(d,2n)}$ alta E	Gamma-PET
^{177}Lu	6 d	$n + ^{176}\text{Yb}$		$^{176}\text{Yb(d,p)}$ alta E	Terapia del cáncer diversos tumores
^{90}Y	64 h			$^{89}\text{Y(d,p)}$ baja-alta E	Terapia del cáncer por radioembolización
^{161}Ho	2.5 h			$^{161}\text{Dy(d,2n)}$ alta E	Terapia del cáncer por electrones Auger
^{125}I	59 d			$^{126}\text{Te(d,3n)}$ alta E	Terapia del cáncer por electrones Auger
^{111}In	2.8 d			$^{112}\text{Cd(d,3n)}$ alta E	Terapia del cáncer por electrones Auger
$^{195\text{m}}\text{Pt}$	4 d			$^{\text{nat}}\text{Pt(d,x)}$ alta E	Terapia del cáncer por electrones Auger

^{18}F : innovation in target designed



Wisconsi Target

	Cyclotron 18 MeV 10 μA			DONES 1.25 mA Wisconsi Updated			DONES 1.25 mA Wisconsi		
	Reacción	Blanco	GBq	Reacción	Blanco	GBq	Reacción	Blanco	GBq
^{18}F	$p+^{18}\text{O} \rightarrow n+^{18}\text{F}$	H_2^{18}O (liq)	142	$d+^{20}\text{Ne} \rightarrow \alpha+^{18}\text{F}$	Ne (gas)	461	$d+^{20}\text{Ne} \rightarrow \alpha+^{18}\text{F}$	Ne (gas)	150

- **Production is justified from social and economic point of view.**
- **At DONES every step, from production to patient, is completely new: INNOVATION.**
- **Radioisotopes can be produced without interfering routine operation of DONES**
- **$^{99}\text{Mo}/^{99\text{m}}\text{Tc}$ can be produced at significant quantities (at least Andalucía).**
- **^{177}Lu could be produced in higher quantities than nuclear reactors.**
- **Many radioisotopes could be produced in significant quantities by neutrons and/or deuterons.**

Thank you



UNIVERSIDAD
DE GRANADA

Javier Praena
Ignacio Porras
Fernando Arias de Saavedra
Andrés Roldán
Elena López Melero (PhD)




Investigación industrial en tecnologías y procesos
aplicados a IFMIF-DONES para poder evolucionar
en el programa de fusión

DONES-EVO



Fernando Mota
Maribel Ortiz

^{177}Lu : where is produced? Nuclear Reactors



300 MBq of ^{177}Lu c.a.
Dose to tumor - 35 Gy




300 MBq of ^{177}Lu n.c.a.
Dose to tumor - 70 Gy

Marion de Jong et al.; 2012 ICTR-PHE

Javier Praena – Universidad de Granada

“Carrier Added”

Neutrons+Lutetium sample




Higher production.

Lower specific activity.

$^{177\text{m}}\text{Lu}$ is produced (0.05%), 160 days.

“Non Carrier Added”


Neutrons+Ytterbium sample





Lower production.

Higher specific activity.

$^{177\text{m}}\text{Lu}$ is negligible



Measure, Experimental Set-Up and ^{176}Yb sample



The sample is a ^{176}Yb oxide powder, (1.5976 g and 99.43% purity) pressed in a 19 mm \varnothing quartz and 2mm thickness.



Kindly provided by Richard Henkelmann (ITG company) and Ulli Koester (ILL). This sample will be recycled for radioisotope production at ITG. ITG supplies of ^{177}Lu to hospitals. As mentioned, new routes are of high interest to produce radioisotopes.

Measurement time from 25/10/2021 to 14/11/2021



Collaboration meeting - 13/12/2022

